DexCom (NASDAQ:DXCM) Rating Reiterated by Cowen

DexCom (NASDAQ:DXCM)‘s stock had its “outperform” rating reaffirmed by research analysts at Cowen in a research note issued to investors on Friday, The Fly reports. They presently have a $300.00 price target on the medical device company’s stock, up from their previous price target of $250.00. Cowen’s target price suggests a potential upside of 5.67% from the company’s current price.

Several other equities research analysts have also issued reports on DXCM. Guggenheim reaffirmed a “buy” rating and issued a $300.00 price objective (up previously from $245.00) on shares of DexCom in a research note on Friday. Stifel Nicolaus upped their price objective on shares of DexCom from $250.00 to $300.00 and gave the stock a “buy” rating in a report on Friday. Jefferies Financial Group increased their target price on shares of DexCom from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Robert W. Baird raised their target price on DexCom from $195.00 to $240.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Finally, BidaskClub cut DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, January 18th. Seven equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. DexCom has a consensus rating of “Buy” and a consensus price target of $256.00.

Shares of DXCM opened at $283.91 on Friday. The firm has a market cap of $22.41 billion, a PE ratio of -145.59 and a beta of 0.80. The firm’s 50 day moving average price is $234.38 and its 200 day moving average price is $190.54. The company has a debt-to-equity ratio of 1.41, a quick ratio of 5.26 and a current ratio of 5.63. DexCom has a twelve month low of $107.44 and a twelve month high of $295.00.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $1.15 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.41. DexCom had a negative net margin of 12.68% and a positive return on equity of 16.16%. The company had revenue of $462.80 million during the quarter, compared to the consensus estimate of $457.00 million. On average, sell-side analysts anticipate that DexCom will post 1.43 earnings per share for the current fiscal year.

In other DexCom news, Director Barbara Kahn sold 9,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $205.14, for a total transaction of $1,846,260.00. Following the completion of the sale, the director now directly owns 2,613 shares in the company, valued at $536,030.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Nicholas Augustinos sold 1,812 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $206.14, for a total value of $373,525.68. The disclosure for this sale can be found here. Insiders sold a total of 47,427 shares of company stock worth $10,539,425 in the last quarter. Insiders own 0.88% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Voya Investment Management LLC increased its position in DexCom by 4.9% during the third quarter. Voya Investment Management LLC now owns 1,306,570 shares of the medical device company’s stock worth $194,992,000 after acquiring an additional 61,506 shares during the period. Blair William & Co. IL raised its stake in DexCom by 4.9% during the 4th quarter. Blair William & Co. IL now owns 1,205,089 shares of the medical device company’s stock valued at $263,601,000 after purchasing an additional 56,352 shares during the last quarter. Fred Alger Management LLC boosted its holdings in DexCom by 66.3% in the 4th quarter. Fred Alger Management LLC now owns 752,206 shares of the medical device company’s stock valued at $164,538,000 after purchasing an additional 299,754 shares during the period. Renaissance Technologies LLC boosted its holdings in DexCom by 1,164.0% in the 4th quarter. Renaissance Technologies LLC now owns 700,243 shares of the medical device company’s stock valued at $153,171,000 after purchasing an additional 644,843 shares during the period. Finally, Westfield Capital Management Co. LP boosted its holdings in DexCom by 5.3% in the 4th quarter. Westfield Capital Management Co. LP now owns 612,124 shares of the medical device company’s stock valued at $133,896,000 after purchasing an additional 30,671 shares during the period. Hedge funds and other institutional investors own 97.85% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Read More: Growth Stocks

The Fly

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.